Carl Icahn's Portfolio
|Ticker||# of Shares||Price||Value|
|View Additional Portfolio Information »|
Carl Icahn is a billionaire financier, ranking #18 on the 2007 Forbes 400 list with an estimated net worth of $14.5 billion.
Icahn built a name for himself in the 1980s as a corporate raider. After keeping quite for years, Icahn made a major comeback as a 'activist investor'. An activist investor agitates companies for changes, including buyouts, share buybacks, and dividend increases.
In 2007, Icahn's activism successfully pushed biotech company MedImmune into a sales agreement with AstraZeneca (NYSE: AZN). Icahn is also involved with biotech company Imclone Systems (Nasdaq: IMCL), where he is Chairman of the Board.
Icahn is also involved with developments at Biogen Idec (Nasdaq: BIIB) and WCI Communities (NYSE: WCI), which both unsuccessfully explored sales. WCI rejected a $22 per share takeover offer from Icahn in early 2007, only to see its stock plummet on the housing slowdown.
In 2008, Icahn targeted Yahoo! (Nasdaq: YHOO) after the Internet company failed to work out an acceptable merger agreement with Microsoft (Nasdaq: MSFT) Microsoft walked away from its bid for Yahoo! after months of bickering.
Market Wrap: Apple's Cook to China: 'Dui Bu Qi'; Tesla Revs Up; Nasdaq Gets Speedier
Icahn Raises Stakes In AMLN, LGF, WMB, YHOO; Cuts Stakes in TIN, LEA
Icahn's Icahn Capital Bumps Stake in Motorola (MOT), Shows New Small Stake in Emisphere (EMIS)
Lear (LEA) volatility Spikes as share sell off on downgrade
Summary of Icahn Capital 13F; New Stake In JCP, Ups Stakes in APC, M